Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals.
Medhat MA, El-Kassas M, Karam-Allah H, Al Shafie A, Abd-Elsalam S, Moustafa E, Hassany SM, Salama M, Abd Elghafar MS, Sayed H, Badr M, Kamal DT, Shamseldeen A, Ossimi A, Moaz I, Esmael HE, Ezz Eldin AM, Ezzat S, Abdelghaffar H, Abdelghaffar K. Medhat MA, et al. Arab J Gastroenterol. 2022 Aug;23(3):165-171. doi: 10.1016/j.ajg.2022.04.005. Epub 2022 May 6. Arab J Gastroenterol. 2022. PMID: 35690556 Free PMC article. Clinical Trial.
Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients.
Eletreby R, Elakel W, Said M, El Kassas M, Seif S, Elbaz T, El Raziky M, Abdel Rehim S, Zaky S, Fouad R, Gamal Eldeen H, Abdo M, Korany M, Yosry A, El Serafy M, El-Sayed MH, ElShazly Y, Waked I, Doss W, Esmat G. Eletreby R, et al. Liver Int. 2017 Apr;37(4):534-541. doi: 10.1111/liv.13266. Epub 2016 Nov 4. Liver Int. 2017. PMID: 27712017
Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience.
El Kassas M, Omran D, Elsaeed K, Alboraie M, Elakel W, El Tahan A, Abd El Latif Y, Nabeel MM, Korany M, Ezzat S, El-Serafy M, ElShazly Y, Doss W, Esmat G. El Kassas M, et al. J Interferon Cytokine Res. 2018 Feb;38(2):81-85. doi: 10.1089/jir.2017.0121. Epub 2018 Jan 22. J Interferon Cytokine Res. 2018. PMID: 29356573
An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens.
El Kassas M, Alboraie M, Omran D, Salaheldin M, Wifi MN, ElBadry M, El Tahan A, Ezzat S, Moaz E, Farid AM, Omar H, Abouelkhair M, Afify S, Elsaeed K, Shazly Y, Doss W, Esmat G. El Kassas M, et al. Expert Rev Gastroenterol Hepatol. 2018 Dec;12(12):1265-1272. doi: 10.1080/17474124.2018.1476137. Epub 2018 May 24. Expert Rev Gastroenterol Hepatol. 2018. PMID: 29757684
Diabetes Association with Liver Diseases: An Overview for Clinicians.
Hamed AE, Elwan N, Naguib M, Elwakil R, Esmat G, El Kassas M, Abd-Elsalam S, Moussa S. Hamed AE, et al. Endocr Metab Immune Disord Drug Targets. 2019;19(3):274-280. doi: 10.2174/1871530318666181116111945. Endocr Metab Immune Disord Drug Targets. 2019. PMID: 30444204 Review.
Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients with Chronic Hepatitis C: Real-world Results from 1716 Patients in Egypt.
Badawi R, Alboraie M, Abd-Elsalam S, Abourahma MZ, Ramadan HK, Ahmed OA, Fouad MHA, Soliman S, Mohareb DA, Haydara T, Alnabawy SM, El Kassas M. Badawi R, et al. Endocr Metab Immune Disord Drug Targets. 2019;19(7):1005-1011. doi: 10.2174/1871530319666190204154830. Endocr Metab Immune Disord Drug Targets. 2019. PMID: 30727931 Clinical Trial.
196 results